Evidence map›Paper›PMID 37615749›Full record

ArticleCellular and molecular life sciences : CMLS2023

An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis.

Lilas Batool, Krithika Hariharan, Yao Xu, Mario Kaßmann, Dmitry Tsvetkov, Björn-Oliver Gohlke, Sylvia Kaden, Manfred Gossen, Bernd Nürnberg, Andreas Kurtz and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Functional Evaluation ofbioRxiv : the preprint server for biology · 2026
    Article
  6. Genotype-phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Observational
  7. Article
  8. Review
  9. Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy.Journal of the American Society of Nephrology : JASN · 2025
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Lilas BatoolBIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Krithika HariharanBIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Yao XuKlinik und Poliklinik für Innere Medizin D-Geriatrie, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald, Germany.
Mario KaßmannKlinik und Poliklinik für Innere Medizin D-Geriatrie, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald, Germany.
Dmitry TsvetkovKlinik und Poliklinik für Innere Medizin D-Geriatrie, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald, Germany.
Björn-Oliver GohlkeDepartment of Information Technology, Science-IT, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Sylvia KadenElectron Microscopy Core Facility, German Cancer Research Center, Heidelberg, Germany.
Manfred GossenBIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Bernd NürnbergDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomics, University of Tübingen, Tübingen, Germany.
Andreas Kurtz *BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. Maik.Gollasch@med.uni-greifswald.de.ORCID http://orcid.org/0000-0003-3301-6546
Maik Gollasch *Klinik und Poliklinik für Innere Medizin D-Geriatrie, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald, Germany. andreas.kurtz@bih-charite.de.
Universitätsmedizin Greifswald · DECharité - Universitätsmedizin Berlin · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DEFraunhofer Institute for Biomedical Engineering · DEGerman Cancer Research Center · DEHelmholtz-Zentrum Hereon · DEUniversity of Tübingen · DE

Funding

Bundesministerium für Bildung und Forschung 01EK1612DBundesministerium für Bildung und Forschung 031A303BDeutsche Forschungsgemeinschaft GO766/18-3Deutsche Forschungsgemeinschaft GO766/22-2Deutsche Forschungsgemeinschaft KA 5422/1-3Deutsche Forschungsgemeinschaft NU53/12-2Deutsche Forschungsgemeinschaft SFB1365Einstein Stiftung Berlin EZ-2016-289Stiftung der Deutschen Wirtschaft ZF4174707MD9
6 · The paper itself

Abstract

Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majority of TRPC6 mutations are missense resulting in increased or decreased calcium influx; however, the fundamental molecular mechanisms causing cell injury and kidney pathology are unclear. We report a novel heterozygous TRPC6 mutation (V691Kfs*) in a large kindred with no signs of FSGS despite a largely truncated TRPC6 protein. We studied the molecular effects of V691Kfs* TRPC6 mutant using the tridimensional cryo-EM structure of the tetrameric TRPC6 protein. The results indicated that V691 is localized at the pore-forming transmembrane region affecting the ion conduction pathway, and predicted that V691Kfs* causes closure of the ion-conducting pathway leading to channel inactivation. We assessed the impact of V691Kfs* and two previously reported TRPC6 disease mutants (P112Q and G757D) on calcium influx in cells. Our data show that the V691Kfs* fully inactivated the TRCP6 channel-specific calcium influx consistent with a complete loss-of-function phenotype. Furthermore, the V691Kfs* truncation exerted a dominant negative effect on the full-length TRPC6 proteins. In conclusion, the V691Kfs* non-functional truncated TRPC6 is not sufficient to cause FSGS. Our data corroborate recently characterized TRPC6 loss-of-function and gain-of-function mutants suggesting that one defective TRPC6 gene copy is not sufficient to cause FSGS. We underscore the importance of increased rather than reduced calcium influx through TRPC6 for podocyte cell death.

Indexed as

Glomerulosclerosis, Focal SegmentalCalciumHumansLoss of Function MutationMutationTRPC6 Cation ChannelCalciumTRPC6 Cation ChannelTRPC6 protein, humanCalciumFSGSPodocyteTRPC6Truncated mutation

Identifiers

PMID37615749
PMCPMC10449997
OpenAlexW4386117011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.